Colesterol e a prevenção de eventos ateroscleróticos: limites de uma nova fronteira by Macedo, Luís Eduardo Teixeira de & E, Faerstein
1DOI:10.1590/S1518-8787.2017051006416
CommentRev Saúde Pública 2017;51:2
Cholesterol and prevention of atherosclerotic 
events: limits of a new frontier
Luís Eduardo Teixeira de MacedoI, Faerstein EI
I Departamento de Epidemiologia. Instituto de Medicina Social. Universidade do Estado do Rio de Janeiro. Rio 
de Janeiro, RJ, Brasil
ABSTRACT
Control of atherosclerotic cardiovascular disease – a highly prevalent condition and one of the 
main causes of mortality in Brazil and worldwide – is a recurrent subject of great interest for 
public health. Recently, three new guidelines on dyslipidemia and atherosclerosis prevention 
have been published. The close release of these important publications is a good opportunity 
for comparison: the Brazilian model has greater sensitivity, the English model does not work 
with risk stratification, and the American model may be overestimating the risk. This will allow 
reflection on current progress and identification of controversial aspects which still require 
further research and debate. It is also an opportunity to discuss issues related to early diagnosis 
and its efficiency as a preventive strategy for atherosclerotic disease: the transformation of risk 
into disease, the gradual reduction of cut-off points, the limitations of the screening strategy, 
and the problem of overdiagnosis.
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INTRODUCTION
Cardiovascular disease (CVD) mortality has increased worldwide as a result of population 
growth and aging. In 2013, it accounted for almost a third of all deaths3. However, 
age-standardized mortality has declined significantly since the 1990s3.
In Brazil, CVD are also the leading cause of death. Nevertheless, they fell 31% between 1996 
and 200720. In the last 40 years, cerebrovascular disease was responsible for more deaths than 
coronary heart disease, probably due to the increased prevalence of high blood pressure, but 
with a declining trend in the 1980s and 1990s11.
In 2010, physical inactivity and inadequate diet accounted for 10% (95%CI 9.2–10.8) of global 
losses in disability-adjusted life years (DALY), which is the sum of years lost due to premature 
death and years lost due to disability, adjusted to their severity weight. High blood pressure 
accounted for a loss of 7% (95%CI 6.2–7.7), and smoking for 6.3% (95%CI 5.5–7.0)10.
The first attempt to overcome the single-factor view of atherosclerotic CVD risk was in New 
Zealand in 1993. But the major advance in the joint use of risk factors came in 1998 with 
the publication of an article by the Framingham Heart Study team. Thus, it was possible to 
estimate the absolute risk of developing coronary heart disease per decade of life according 
to gender and age, systolic blood pressure, total cholesterol, HDL-cholesterol, diagnosis of 
diabetes, and knowledge of smoking habits12.
Recently, three new guidelines on dyslipidemia and atherosclerosis prevention have 
been released. In October 2013, the Brazilian Society of Cardiology published “V Diretriz 
sobre Dislipidemias e Prevenção da Aterosclerose” (V Guideline on Dyslipidemias and 
Atherosclerosis Prevention)25. One month later, the American College of Cardiology and the 
American Heart Association published the “Guideline on the Assessment of Cardiovascular 
Risk”4. Finally, in September 2014 in England, the National Institute for Health and Care 
Excellence published an update on the modification of serum lipids aimed at primary and 
secondary prevention of cardiovascular diseasesa.
The new guidelines recommend different therapeutic interventions, but they are all based 
on individual absolute risk, estimated from different multivariate statistical models of risk 
prediction. Our Table compares the main characteristics of each one of these guidelines. 
There are several aspects worth considering.
Firstly, the outcomes for which the risk is estimated differ. Simply expanding the clinical 
possibilities for which the risk is calculated increases the likelihood that they are present, 
and this will always be translated as greater absolute risk.
A second aspect worth considering is the relationship between age and risk levels. It is 
known that absolute risk of atherosclerotic disease increases with age; on the other hand, 
the relative weight of the other risk factors in the composition of this absolute risk decreases. 
Individually, age can select the groups with the highest individual risk. Regarding coronary 
and cerebrovascular events, a cut-off point of 55 years could be used to identify 96% of 
future fatalities23. In other words, the impact of lowering LDL-cholesterol on the absolute 
risk reduction of an atherosclerotic event decreases with age.
In the three guidelines, absolute risk is presented in levels graded as low, medium and high. 
However, both the variables that make up the equations and the limits between each risk 
range differ between the guidelines. Therefore, the estimated risk and, consequently, the 
recommended intervention for a same person may differ according to the guideline chosen.
It is common for clinical trial outcomes to be presented to practitioners in terms of relative 
risk reduction. However, decision-making requires absolute measures, i.e., absolute risk 
reduction (ARR)19. An example is shown by comparing screening strategies that generate the 
same relative risk reduction of 20% in diseases with different mortality rates. The first disease 
a National Institute for Health 
and Care Excellence. Lipid 
modification: cardiovascular risk 
assessment and the modification 
of blood lipids for the primary 
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has a 5% mortality rate, and screening would reduce it to 4% (20% of 5%). The absolute risk 
reduction is 1% (5% minus 4%), and the number of people needed for screening18 is 100 (1 
divided by 1% [1/ARR]). For every 100 people not screened, five will die, and for every 100 
people screened, four will die. That is, for every 100 people screened, it is possible to save a 
life. The second disease has a lower mortality rate of 0.5%, and therefore screening will reduce 
mortality to 0.4% (20% of 0.5%). The absolute risk reduction is 0.1% (0.5% minus 0.4%), and 
the number of people needed for screening is 1,000 (1 divided by 0.1%). In this case, 1,000 
people would have to be screened to avoid one death19.
The Framingham Study has a long history of producing multivariable predictive risk 
models. The use of tables associating the occurrence of risk factors with the given score, 
which will result in a total score, stems from the observation of the weight each factor 
has in these equations. If, on the one hand, the resource contributes to operational ease, 
on the other it oversimplifies the multifactorial nature of atherosclerotic disease and 
may generate loss of information and precision in the results. In addition, the ethnic 
composition of the study population is quite different compared to the rest of the world 
and to Brazil in particular22.
Table. Summary of the main characteristics of new national and international guidelines for cholesterol and atherosclerotic disease.
Guideline
SBC V Guideline ACC/AHA Guideline NICE 
Country Brazil United States England
Release October/2013 November/2013 September/2014
Age of assessed individuals Adults > 30 years Adults > 20 years Adults > 40 years
Period related to absolute risk 10 years or throughout lifea
10 years or throughout 
lifeb
10 yearsc
Risk prediction tool Global Risk Score Pooled Cohort Equations QRISK 2
Outcomes related to risk
Acute Myocardial Infarction (AMI); Stroke; 
Peripheral Vascular Disease; or Congestive Heart 
Failure
AMI; Death by Coronary 
Heart Disease; fatal and 
non-fatal stroke
AMI; Death by Coronary 
Heart Disease; fatal and 
non-fatal stroke
Risk level: Men Women
High ≥ 20.0% > 10.0% > 7.5% No risk stratificationd
Intermediate 5.0% a 19.0% 5.0% a 10.0% 5.0% a 7.5%
Low 0% a 4.0% 0% a 4.0% < 5.0%
Sugested therapy Antilipemics Statinsf Statinsf
Previous LDL-cholesterol limits Low risk: < 160 mg/dle Low risk:< 160 mg/dl
Secondary prevention 
only
Medium risk: < 130 mg/dle Medium risk:< 130 mg/dl
High risk: < 100 mg/dle High risk: < 100 mg/dl
Current LDL-cholesterol limits Low risk: individualized limit No limits
Secondary prevention 
only
Medium risk: < 100 mg/dle
High risk: < 70 mg/dle
ACC: American College of Cardiology; AHA: American Heart Association; NICE: National Institute for Health and Care Excellence; QRISK: QRESEARCH 
Cardiovascular Risk Algorithm
a Indicated for individuals with low risk over 10 years and aged > 45.
b Indicated for individuals with low risk over 10 years; calculated for a 30-year period.
c Risk also presented for longer periods, with continuous variable.
d Uses 10,0% and 20,0% of absolute risk as reference point for therapy indication.
e Stricter limits compared to “IV Diretriz sobre Dislipidemias e Prevenção da Aterosclerose da Sociedade Brasileira de Cardiologia” (Afiune Neto A, 
Souza AD, Lottenberg AMP, Chacra AP, Faludi AA, Loures-Vale AA, et al. IV Diretriz Brasileira Sobre Dislipidemias e Prevenção da Aterosclerose do 
Departamento de Aterosclerose da Sociedade Brasileira de Cardiologia. Arq Bras Cardiol. 2007;88(Supl I):1-19).
f Increased therapy intensity for higher risks.
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The validity of using these risk scores can also be questioned. The assimilation of a predictive 
model for clinical practice requires the prior performance of four distinct evaluations. First, 
identification of the variables that will compose the model. Then, validation of the tool in 
the population where it was generated, when investigating its capacity to distinguish cases 
from non-cases. Next, validation in external populations, or calibration, when comparing 
calculated risks with observed risks. And, finally, analysis of the impact of the use of the tool 
in actual clinical practice1. In the case of the US guidelines, if on the one hand there was 
a concern with recommending only those interventions already evaluated in randomized 
clinical trials, on the other the same criterion was not applied in selecting the risk prediction 
model. Indeed, application of the Pooled Cohort Equation in the population of the Women’s 
Health Initiative, Women’s Health Study and the Physician’s Health Study indicated 
overestimation of cardiovascular risks, which reached more than 150%17.
These guidelines are not protocols for the treatment of dyslipidemias or atherosclerosis, 
but for the prevention of ischemic events resulting from atherothrombotic phenomena, 
based on control of serum cholesterol levels. Thus, it is relevant to go back to the conceptual 
basis of preventive medicine systematized by Leavell and Clark8. The natural history model 
proposed by the authors presents the process of illness in distinct phases. Initially, there 
is a phase of susceptibility, when exposure to risks and induction of disease occurs. Then 
the disease begins, but without manifest signs or symptoms, in a phase called subclinical, 
or latency period. The next step is symptomatic disease, also called the clinical phase. The 
idea of predisease originated from early 20th century oncology9. The term prediabetes 
appeared in the medical literature around 19406; prehypertension, in turn, is a more recent 
term, introduced in 20037. Thus, the predisease phase precedes the disease stage – including 
subclinical. That is, it concerns events that happen still in the induction period.
A predisease does not always progress to the next stage. Among people with prehypertension, 
20% to 30% stabilize their blood pressure levels over time, without undergoing any 
intervention. Likewise, individuals with fasting blood glucose levels between 100 mg/dl 
and 110 mg/dl, conceptually in a prediabetes state, when monitored for up to 20 years 
did not present a higher risk than those of individuals with normal glycaemia for both 
the development of retinopathy, nephropathy or neuropathy and the occurrence of major 
cardiovascular events7.
Subclinical atherosclerosis comprises states ranging from initial reactions to risk exposure, 
especially endothelial dysfunction, to the presence of calcified, inflamed, and unstable 
atheromatous plaques (Figure). It makes epidemiological sense to observe that, in a causal 
chain, the more distal the exposure, the lower its strength of association with the outcome2. 
That is, the strength of association between exposure to hypercholesterolemia and acute 
myocardial infarction should be lower than that observed between the calcified atheromatous 
plaque and infarction.
Thus, a question arises: at what point in the natural history of atherosclerosis will the 
detection of abnormalities decrease the likelihood of advanced disease or death? If early 
diagnosis of a disease in the clinical phase is always desired, the same may not be true 
regarding the previous phases of atherosclerotic disease. At least, not until randomized 
clinical trials have assessed the impact of therapeutic intervention based on the screening 
of each one of these stages of the pathophysiological chain and proven the effectiveness of 
this strategy.
There are two different prevention strategies: the modification of population risks and the 
modification of individual risks. The former stems from the observation that the variability of 
a given characteristic within a specific population – serum cholesterol, for example – tends to 
form a unimodal continuous distribution14. The population prevention strategy aims to shift 
the whole distribution of risk frequency in a favorable direction. To this end, it is necessary 
to conduct interventions that modify the behavior of the whole society. It is a strategy with 
a longer reach in the causal chain and of more lasting effect19.
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The prevention strategy that focuses on high individual risk interferes with a smaller part 
of the total population and offers cost-effective interventions. It is narrow in scope, since it 
does not modify adverse behaviors or unjust social structures. It has a palliative, local and 
temporary effect and little capacity to reduce the population burden of disease19.
Screening is a prevention strategy that seeks patients in an asymptomatic subpopulation with 
high individual risk to impose treatment that modifies the natural history of the disease16. 
The guidelines in question start out from this procedure, but once the risk is stratified, 
treatment is soon proposed. However, two steps are missing in this process: performance 
of screening and diagnostic tests. Proposing treatment for the entire high-risk group will 
inevitably increase the occurrence of false-positives and overdiagnosis.
The medical literature has modified the limits that define important diseases related to 
atherosclerosis, with great impact in the calculation of their prevalence. In the United States, 
the decrease in requirements regarding total serum cholesterol, from 240 mg/dl to 200 mg/dl, 
added 42,647,000 people to the patient group (+86%). For every 100 people diagnosed 
Figure. Sequence of events in the pathophysiology of atherosclerotic cardiovascular disease.
Exposure to atherosclerosis risk factors
Endothelial dysfunction
Expression of adhesion molecules in the endothelium
Clot formation in the artery lumen
Ischemia
Vulnerable plaque fracture
Inux of lipids and macrophages in the intima-media space
Formation of an atheromatous plaque under chronic inammation
Progressive scarring and calcication of plaque due to inammation
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with dyslipidemia based on the new limits, 78 will never progress to the clinical phase of 
the disease. The diagnosis and treatment of this population group are called, respectively, 
overdiagnosis and overtreatment24.
However, it is not possible to differentiate individuals whose clinical situation will reach 
clinical significance from those who will never cross that border. It is possible to recognize 
overdiagnosis by comparing the incidence of clinical disease among screened and unscreened 
populations; by identifying subclinical disease during necropsy studies; and by the fact that 
there are poorly calibrated predictive models that overestimate morbidity and mortality24.
Excessive use of certain screening and diagnostic tests is an important component of 
health care cost in many countries – in the United States, over $2.2 trillion in 2008. The 
American College of Physicians has been involved in the effort to differentiate the value 
of an intervention based on the identification of its risks, costs and benefits15. More than 
US$200 billion may be wasted annually in the United States with unnecessary treatment13, 
where preventable medical errors committed in hospital environments are now the sixth 
leading cause of death21.
It is essential for Brazilian health researchers and practitioners to also debate the excesses 
involving asymptomatic individuals in the name of prevention, based on the belief – not 
necessarily always true – that the earlier the diagnosis, the better.
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